CMAB Biopharma

CMAB Biopharma Inc. (CMAB), is a full-service contract development and manufacturing organization (CDMO) established in 2017, which is dedicated to providing process development and manufacturing services for biologic products. We provide bespoke development manufacturing services of antibodies and biologics for clients in China and across the globe. Our adaptable, service-oriented business enables clients to take their innovative concepts for tomorrow’s medicines from DNA to clinical product today. Located in Suzhou’s BioBAY Park, CMAB’s manufacturing facility will provide services for the development of manufacturing process, analytical method, formulation, and the manufacture of biologic drug substances and drug products. Our initial facility will generate pre-clinical and early-stage clinical (Phase I/II) products, using manufacturing that follows global GMP standards, including those of the China National Medical Products Administration (NMPA), US Food & Drug Administration (21 CFR), European Medicines Agency (Eudralex), WHO, and harmonized PIC/S and ICH standards. CMAB has quickly built up a team with strong expertise in the biologics CDMO industry. The founding CMAB management team have solid experience gained from international bio-pharmaceutical companies and have collectively delivered more than 100 CDMO projects resulting in at least 40 IND applications for biological drugs. Currently, CMAB has over 160 employees and targets expansion to a strength of more than 200 staff at the end of 2019. In January 2018, CMAB completed its series A financing of US$38 million, which was led by C-Bridge Capital and BioBAY, with I-Bridge Capital and Qianhai FoF fund joining the consortium. A series B financing round of US$34 million was secured in April 2018, led by CD Capital, with joint participation by C-Bridge Capital, Cormorant, Qianhai FoF Fund and Tigermed. Learn more about CMAB at our website: www.cmabbio.com or contact us directly at hello@cmabbio.com